We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 81.64%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CFRX
51
DELISTED
ContraFect Corporation
CFRX
$7.08M 0.07%
5,057
– –
IMGN
52
DELISTED
Immunogen Inc
IMGN
$6.15M 0.06%
3,015,353
– –
DMTX
53
DELISTED
Dimension Therapeutics, Inc
DMTX
$5.45M 0.05%
1,251,881
– –
AGIO icon
54
Agios Pharmaceuticals
AGIO
$2.08B
$5.37M 0.05%
128,666
-79,249
-38% -$4.16M
CPRX
55
DELISTED
Catalyst Pharmaceutical
CPRX
$5.36M 0.05%
5,102,153
– –
INSM icon
56
Insmed
INSM
$22.6B
$5.29M 0.05%
400,000
– –
ARCT icon
57
Arcturus Therapeutics
ARCT
$161M
$4.91M 0.05%
333,766
– –
RIGL icon
58
Rigel Pharmaceuticals
RIGL
$705M
$4.8M 0.05%
+201,888
New +$5.78M
BIIB icon
59
Biogen
BIIB
$31.7B
$4.68M 0.05%
+16,500
New +$4.89M
GNMX
60
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.56M 0.04%
880,539
– –
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$4.52M 0.04%
217,328
– –
LOXO
62
DELISTED
Loxo Oncology, Inc
LOXO
$4.42M 0.04%
137,735
– –
STML
63
DELISTED
Stemline Therapeutics, Inc.
STML
$3.57M 0.04%
333,497
– –
RARE icon
64
Ultragenyx Pharmaceutical
RARE
$2.5B
$3.52M 0.03%
50,000
-50,000
-50% -$3.55M
AKTX
65
Akari Therapeutics
AKTX
$14.3M
$3.5M 0.03%
621
– –
NERV icon
66
Minerva Neurosciences
NERV
$185M
$3.04M 0.03%
32,351
– –
ASMB icon
67
Assembly Biosciences
ASMB
$492M
$3.04M 0.03%
20,833
– –
RXDX
68
DELISTED
Ignyta, Inc.
RXDX
$3.03M 0.03%
571,000
– –
RNAC icon
69
Cartesian Therapeutics
RNAC
$222M
$3.01M 0.03%
5,857
-108
-2% -$63.1K
NTRA icon
70
Natera
NTRA
$36.1B
$2.92M 0.03%
249,269
-200,731
-45% -$2.21M
ADMS
71
DELISTED
Adamas Pharmaceuticals
ADMS
$2.92M 0.03%
172,630
– –
EPZM
72
DELISTED
Epizyme, Inc
EPZM
$2.81M 0.03%
232,481
– –
IONS icon
73
Ionis Pharmaceuticals
IONS
$9.12B
$2.73M 0.03%
57,140
– –
RARX
74
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.7M 0.03%
+177,952
New +$2.42M
VIRX
75
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.69M 0.03%
21,190
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Baker Bros. Advisors held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Baker Bros. Advisors's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Baker Bros. Advisors's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Baker Bros. Advisors fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 7 in Q4 2016.
  • Baker Bros. Advisors's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.